Drug Trial Radar · NCT01568073
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Last checked: Nov 19, 2026Latest source record: Sep 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Mar 2011
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 83 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa Decarboxylase Inhibitor (DDCI), in patients with Parkinson's Disease (PD) and end-of-dose motor fluctuations.
Conditions
- Parkinson's Disease
Interventions
BIA 9-1067Drug
5, 25 and 50 mg of BIA 9-1067 (once-daily)
EntacaponeDrug
200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
PlaceboDrug
200 mg
LevodopaDrug
CarbidopaDrug
DOPA decarboxylase inhibitor
BenserazideDrug
DOPA decarboxylase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,Time frame: 14 to 15 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bial - Portela & Cª, S.A.
S. Mamede Do Coronado, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.